Correction to: D.J. Jackson, M.E. Wechsler, G. Brusselle, R. Buhl. Targeting the IL‐5 pathway in eosinophilic asthma: A comparison of anti‐IL‐5 versus anti‐IL‐5 receptor agents. Allergy 2024; 79: 2943‐2952. https://doi.org/10.1111/all.16346

Original sentence: However, costs may differ between different countries, where, for example in Spain, mepolizumab can be selfadministered and is a more cost-effective option than benralizumab or reslizumab. 62New sentence: From a cost-effectiveness 5-year simulation model conducted in Spain, benralizumab was more effective (benralizumab: 2.87 exacerbations, 52.21 QALYs; mepolizumab: 4.70 exacerbations, 51.39 QALYs; dupilumab: 5.11 exacerbations, 51.30QALYs) and less costly (total cost per patient, benralizumab: 56,093.57;mepolizumab: 59,280.45;dupilumab: 62,991.76)compared with mepolizumab and dupilumab for patients with uncontrolled severe eosinophilic asthma. 62